| Budget Amount *help |
¥23,530,000 (Direct Cost: ¥18,100,000、Indirect Cost: ¥5,430,000)
Fiscal Year 2019: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
Fiscal Year 2018: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
Fiscal Year 2017: ¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
|
|---|
| Outline of Final Research Achievements |
In this research project, we focused on the activated RAS mutations (KRAS, HRAS, NRAS), which have been detected at different mutation rates depending on cancer tissues, and analyzed the oncogenic process using a primary epithelial cell culture system. Analysis with lung epithelial cells confirmed the different oncogenic functions of RAS mutations between bronchial epithelial cells and small airway epithelial cells of the lung. We also searched for small molecules that are selectively effective against specific RAS mutations and identified several candidate compounds. These compounds were found to be effective against RAS mutations in the experiment with cell lines and in a mouse transplantation model.
|
